Latest Events

The GalXCTM RNAi Technology Platform

GalXCTM is a proprietary RNAi technology platform that advances the development of next-generation RNAi-based therapies that act by silencing disease-driving genes in the liver. GalXC molecules are designed for infrequent subcutaneous administration.

Unlocking the Potential of RNAi

RNA interference (RNAi) is a natural biological method for silencing or “turning off” specific genes known to cause or drive disease. In the RNAi process, small, carefully selected molecules of RNA inhibit the expression of these harmful genes by causing the targeted destruction of their messenger RNAs (mRNAs). RNAi has the potential to generate a revolution in medicine.on in medicine.

Molecular Therapy publishes a paper demonstrating how the use of DsiRNA compounds inhibit tumor growth by silencing β-catenin, a key oncogene in hepatocellular carcinoma (HCC).

Apr 2014

Dicerna initiates a Phase 1 study of DCR-MYC in patients with solid tumors and hematologic malignancies.

Oct 2014

Dicerna presents preclinical data indicating the rapid and durable effect of DCR-PH1 in a mouse model of primary hyperoxaluria type 1 (PH1), at the 10th annual meeting of the Oligonucleotide Therapeutics Society in San Diego, Calif.

Dicerna presents positive preclinical data on DsiRNA therapeutics targeting MYC and β-catenin at the American Association of Cancer Research (AACR) MYC meeting.

Feb 2015

Dicerna announces dosing of the first patient in a Phase 1b/2 clinical trial of DCR-MYC for the treatment of advanced hepatocellular carcinoma (HCC).

Feb 2016

In a mouse model of Primary Hyperoxaluria Type 1, the data demonstrate that DsiRNAs targeting HAO1 expression produces potent and durable responses, and that these responses can be reliably monitored not only in mice but also in non-human primates.

Jun 2016

Dicerna invented GalXC, a proprietary next-generation RNAi technology platform, to rapidly identify new therapeutic agents that silence disease-driving genes in the liver and to efficiently advance these therapies into the clinic.

Sept 2016

The β-catenin/Wnt pathway is among the most functionally validated targets for hepatocellular carcinoma and colorectal cancers. Dicerna demonstrated that inhibition of activated Wnt signaling causing tumor regression and terminal differentiation in well-established colorectal tumors.

Our Mission

Dicerna is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare diseases, chronic liver diseases, cardiovascular disease, and viral liver infectious diseases. The Company is using its proprietary GalXC RNAi technology platform to build a broad pipeline in these therapeutic areas.